In silico drug re-purposing against African sleeping sickness using GlcNAc-PI de- N -acetylase as an experimental target

Type de record:

paper

Créateur:

MayD.

Éditeur:

Elsevier BV

Hôte:

Visit

Licenses

https://www.elsevier.com/tdm/userlicense/1.0/

Similaires

Novel lead compounds in pre-clinical development against African sleeping sicknessThe Molecular Dynamics of <i>Trypanosoma brucei</i> UDP‐Galactose 4′‐Epimerase: A Drug Target for African Sleeping SicknessInsights from aquaporin structures into drug-resistant sleeping sicknessInvestigation of thiazolyl–benzothiophenamides as potential agents for African sleeping sicknessMolecular epidemiology of African sleeping sicknessAn In Silico QSAR Model Study Using Electrophilicity as a Possible Descriptor Against T. Brucei

Novel lead compounds in pre-clinical development against African sleeping sickness

This article reviews the recent progress in drug development against the African sleeping sickness.

The Molecular Dynamics of <i>Trypanosoma brucei</i> UDP‐Galactose 4′‐Epimerase: A Drug Target for African Sleeping Sickness

During the past century, several epidemics of human African trypanosomiasis, a deadly disease caused

Insights from aquaporin structures into drug-resistant sleeping sickness

Trypanosoma brucei is the causal agent of African trypanosomiasis in humans and animals, the latter

Investigation of thiazolyl–benzothiophenamides as potential agents for African sleeping sickness

African sleeping sickness is a potentially fatal neglected disease affecting sub-Saharan Africa.

Molecular epidemiology of African sleeping sickness

SUMMARY Human sleeping sickness in Africa, caused by Trypanosoma brucei spp. raises a number of q

An In Silico QSAR Model Study Using Electrophilicity as a Possible Descriptor Against T. Brucei

Human African trypanosomiasis (HAT) is a vector-borne sleeping sickness parasitic disease spread thr